Compile Data Set for Download or QSAR
Report error Found 1467 Enz. Inhib. hit(s) with all data for entry = 11948
TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664033(N-(5-((2-(6-azaspiro[3.4]octan- 6-yl)ethyl)carbamo...)
Affinity DataIC50: 0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664160(N-(5-(3-(2,2-dimethylpyrrolidin- 1-yl)propanamido)...)
Affinity DataIC50: 0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664200(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664201(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664203(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664204(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664205(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664241(N-(5-(2-(5-azaspiro[2.4]heptan- 5-yl)acetamido)-2-...)
Affinity DataIC50: 0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664353(N-(5-(2-(3,3-Dimethylazetidin- 1-yl)acetamido)-2- ...)
Affinity DataIC50: 0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664388(N-(5-(2- (cyclobutylamino)acetamido)- 2-methylpyri...)
Affinity DataIC50: 0.100nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM663925(N-(5-((2-(2- azabicyclo[2.2.2]octan-2- yl)ethyl)ca...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM663930(2-(1-cyclopropyl-1H-pyrazol-4- yl)-N-(5-((2-(2,2- ...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM663993((S)-N-(5-(2-(3- ethylmorpholino)acetamido)-2- meth...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664064(N-(5-((2-(2- azabicyclo[2.2.2]octan-2- yl)ethyl)ca...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664079(N-(5-((2-(5-azaspiro[2.4]heptan- 5-yl)ethyl)carbam...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664097(N-(5-((2-(2- azabicyclo[2.2.2]octan-2- yl)ethyl)ca...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664100(N-(5-((2-(2- azabicyclo[2.2.2]octan-2- yl)ethyl)ca...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664139(2-(1,5-Dimethyl-1H-pyrazol-4- yl)-N-(2-methyl-5-((...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664145(N-(5-((2-(2,2- Dimethylpyrrolidin-1- yl)ethyl)carb...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664147(2-(2-Methoxypyridin-3-yl)-N- (2-methyl-5-((2-(2- m...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664148(2-(2-Methoxypyridin-3-yl)-N- (2-methyl-5-((2-(pyrr...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664152(N-(5-(2-(2,2-dimethylpyrrolidin- 1-yl)acetamido)-2...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664161((R)-2-(2-methoxypyridin-3-yl)- N-(2-methyl-5-((2-(...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664172((S)-(1-methylpyrrolidin-2- yl)methyl (5-(2-(2- met...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664173(2-(2,2-dimethylpyrrolidin-1- yl)ethyl (5-(2-(2- me...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664174(2-(pyrrolidin-1-yl)propyl (5-(2- (2-methoxypyridin...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664176((S)-(1-methylpyrrolidin-2- yl)methyl (6-methyl-5-(...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664190(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664191(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664192(2-(2-acetamidopyridin-4-yl)-N- (5-(2-(3,3-dimethyl...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664194(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664196(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664202(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664218((S)-2-(2-methoxypyridin-3-yl)- N-(2-methyl-5-((2-(...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664226((R)-N-(5-(2-(1- isopropylpyrrolidin-2- yl)acetamid...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664228((S)-N-(5-(2-(2- ethylmorpholino)acetamido)-2- meth...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664230(2-(2-methoxypyridin-3-yl)-N-(2- methyl-5-(2-(pyrro...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664237(N-(5-(2-(2-oxa-7- azaspiro[4.4]nonan-7- yl)acetami...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664238(N-(5-(2-(5-azaspiro[2.5]octan-5- yl)acetamido)-2-m...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664240((S)-N-(5-(2-(1- isopropylpyrrolidin-2- yl)acetamid...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664270(N-(5-(2-(1-azaspiro[3.3]heptan- 1-yl)acetamido)-2-...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664271(2-(1,3-dimethyl-1H-pyrazol-4- yl)-N-(5-(1-isopropy...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664274(2-(1,5-dimethyl-1H-pyrazol-4- yl)-N-(5-(1-isopropy...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664286(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664304(N-(5-((2-(3,3-dimethylazetidin- 1-yl)ethyl)carbamo...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664311(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664316(N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-m...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664320(N-(5-(2-(7-oxa-2- azaspiro[3.5]nonan-2- yl)acetami...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664322(2-(2-methoxypyridin-3-yl)-N-(2- methyl-5-(2-(3-met...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM664325(N-(5-(2-(1-azaspiro[3.3]heptan- 1-yl)acetamido)-2-...)
Affinity DataIC50: 0.200nMAssay Description:Stock Solutions:Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1467 total ) | Next | Last >>
Jump to: